Pfizer’s Beqvez (fidanacogene elaparvovec) Receives Health Canada’s Approval for the Treatment of Hemophilia B
Shots:
- The approval was based on the results from the P-III (BENEGENE-2) clinical trial evaluating the safety & efficacy of Beqvez in patients (n=45) aged 18-65yrs. with moderately severe to severe hemophilia B (congenital Factor IX (FIX) deficiency)
- The primary objective of the study was to evaluate the annualized bleeding rate (ABR) in patients treated with gene therapy vs FIX prophylaxis replacement regimen
- Beqvez is a gene therapy that leverages AVV capsid to deliver high-activity human FIX gene. This therapy was developed as a one-time treatment for patients with hemophilia B to produce FIX within the body
Ref: Newswire | Image: Pfizer
Related News:- Nona Biosciences and Pfizer Sign a License Agreement to Develop and Commercialize HBM9033 for Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
